First Manhattan’s CRISPR Therapeutics CRSP Stock Holding History

First Manhattan’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-885	Closed	-$60.3K	–	798
2024 Q1	$60.3K	Buy	885 +770	+670%	+$55.1K	﹤0.01%	844
2023 Q4	$7.2K	Sell	115 -167	-59%	-$9.23K	﹤0.01%	1159
2023 Q3	$12.8K	Buy	282 +232	+464%	+$12K	﹤0.01%	1088
2023 Q2	$2.81K	Hold	50	–	–	﹤0.01%	1279
2023 Q1	$2.26K	Hold	50	–	–	﹤0.01%	1374
2022 Q4	$2.03K	Hold	50	–	–	﹤0.01%	1533
2022 Q3	$3K	Hold	50	–	–	﹤0.01%	1376
2022 Q2	$3K	Hold	50	–	–	﹤0.01%	1399
2022 Q1	$3K	Sell	50 -634	-93%	-$39.8K	﹤0.01%	1441
2021 Q4	$51K	Sell	684 -1,800	-72%	-$157K	﹤0.01%	993
2021 Q3	$278K	Buy	2,484 +2,434	+4,868%	+$306K	﹤0.01%	670
2021 Q2	$8K	Hold	50	–	–	﹤0.01%	1308
2021 Q1	$6K	Sell	50 -300	-86%	-$45.3K	﹤0.01%	1306
2020 Q4	$53K	Buy	350 +50	+17%	+$5.91K	﹤0.01%	892
2020 Q3	$25K	Hold	300	–	–	﹤0.01%	995
2020 Q2	$22K	Hold	300	–	–	﹤0.01%	1015
2020 Q1	$12K	Hold	300	–	–	﹤0.01%	1099
2019 Q4	$18K	Hold	300	–	–	﹤0.01%	1058
2019 Q3	$12K	Hold	300	–	–	﹤0.01%	1130
2019 Q2	$14K	Hold	300	–	–	﹤0.01%	1142
2019 Q1	$10K	Hold	300	–	–	﹤0.01%	1194
2018 Q4	$8K	Hold	300	–	–	﹤0.01%	1190
2018 Q3	$13K	Hold	300	–	–	﹤0.01%	1188
2018 Q2	$17K	Buy	+300	New	+$17.1K	﹤0.01%	1121

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

First Manhattan's CRSP Position: Q2 2024 in Review

First Manhattan sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 885 shares — an estimated $60.3K sold.

First Manhattan first reported a position in CRSP in Q2 2018 and held it in 24 quarters. The position peaked at $278K in Q3 2021. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

First Manhattan reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 885 CRISPR Therapeutics shares in Q2 2024, an estimated $60.3K.
First Manhattan first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 24 quarters.
First Manhattan's CRISPR Therapeutics position peaked at $278K in Q3 2021.
449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.